USFDA concludes inspection of Lupin’s Somerset facility

09 Nov 2020 Evaluate

United States Food and Drug Administration (USFDA) has concluded inspection at Lupin’s subsidiary Novel Laboratories Inc. based in Somerset, NJ. The inspection commenced on September 10, 2020 and concluded on November 5, 2020. The duration of the inspection was prolonged due to COVID-related delays and challenges.
The inspection at the Somerset, NJ facility closed with thirteen observations.

The company is confident of addressing these observations and will work closely with the agency to address their concerns. The company does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility. The facility contributes less than 5 percent of its global revenues.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×